亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

枸櫞酸馬羅匹坦

 
 
單價(jià) 50000.00 / 千克對(duì)比
銷量 暫無(wú)
發(fā)貨 山東濟(jì)南市付款后3天內(nèi)
庫(kù)存 50千克起訂1千克
品牌 番訊生物
含量 99.0%
顏色 白色或類白色
過(guò)期 長(zhǎng)期有效
更新 2024-05-28 18:37
 

濟(jì)南川成醫(yī)藥科技開發(fā)有限公司

企業(yè)會(huì)員第12年
資料未認(rèn)證
保證金未繳納
詳細(xì)說(shuō)明

 

公司自產(chǎn)品種有布格替尼,賽爾帕替尼LOXO-292,TAS6417,卡博替尼,佐利替尼AZD3759, 妥卡替尼,舒沃替尼dzd9008,莫博替尼TAK788, 己二酸他立替尼AB-106, BDTX-189, 宗爾替尼BI-1810631,枸櫞酸托瑞米芬, BI-4142枸櫞酸馬羅匹坦,恩氯米芬檸檬酸鹽,RAD-140,BLU-451(LNG451)等產(chǎn)品以及相關(guān)中間體。

塞爾帕替尼LOXO-292   CAS:2152628-33-4

莫博替尼TAK788  CAS : 1847461-43-1

TAS6417 CAS :1661854-97-2

布格替尼AP26113 CAS: 1197953-54-0

AZD3759  CAS:1626387-80-1

卡博替尼  CAS:849217-68-1

BDTX-189 CAS:2414572-47-5

DZD9008    CAS:2370013-49-1

妥卡替尼CAS:937263-43-9

恩氯米芬檸檬酸鹽 CAS:7599-79-3

3-氯-6-三氟甲基噠嗪  CAS:258506-68-2

 

 

 

舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
LOXO292塞爾帕替尼 布格替尼 恩氯米芬檸檬酸鹽 恩氯米芬檸檬酸鹽 BI-4142 琥珀酸莫博替尼TAK788 宗爾替尼BI-1810631 他立替尼AB-106 枸櫞酸托瑞米芬
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |